NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen

Trial Profile

NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs NGR-TNF (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Sponsors MolMed
  • Most Recent Events

    • 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
    • 04 Jun 2012 Three-year follow-up data were presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a MolMed media release.
    • 17 May 2012 Results will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a MolMed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top